Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment
-
Indian Pharmacy Practise Regulations 2015 – Courtesy(Pharmabiz.com)
Pharma Live, , Regulatory Affairs, 0
The government of India last January issued a notification entitled Pharmacy Practice Regulations 2015 aimed at enhancing the status...
-
A REVIEW ON GOOD MANUFACTURING PRACTICE (GMP) FOR MEDICINAL PRODUCTS
Pharma Live, , Regulatory Affairs, 0
ABOUT AUTHORS:Vikash Kumar Chaudhari1*, Vijay Yadav2, Praveen Kumar Verma1, Amit Kumar Singh21Department of Pharmaceutical Chemistry,2Department of Pharmacognosy,Kunwar Haribansh Singh...
-
Root Cause Analysis (RCA)
Pharma Live, , Regulatory Affairs, 0
Identifying the root cause for market complaints, out of specifications (OOS), deviations can be challenging, but a number of...
-
-
MHRA Guide to Safety , Quality and Efficacy
Pharma Live, , Regulatory Affairs, 0
MCA guide for safety quality and efficacy
-
FDA Form 483 – Frequently Asked Questions!
Pharma Live, , Regulatory Affairs, 0
FDA Form 483 Frequently Asked Questions Q: When is an FDA Form 483 issued? A: An FDA Form 483 is...
-
Telmisartan: no double-dipping says CJEU, as it avoids answering all the questions – Courtesy (The SPC Blog)
Pharma Live, , Regulatory Affairs, 0
The Court of Justice of the European Union (CJEU) delivered its ruling in Case C‑577/13, Actavis Group PTC EHF, Actavis UK...
-
The moving parts of orphan drug development – Courtesy (PMLiVe)
Pharma Live, , Regulatory Affairs, 0
The very mention of orphan drugs is enough to give some pharma accountants the jitters. Chasing a cure for...
![](https://interactivepharm.com/wp-content/uploads/2022/08/Show-your.jpg)